Key result
Phospho-mimetic cTnIS43/45D drives cardiac dysfunction and accelerates heart failure via early mitochondrial impairment.
Why the study?
Chronic cTnI Ser43/45 phosphorylation causes contractile dysfunction in cardiac myocytes, but its in vivo impact was less clear.
Chronic cTnI Ser43/45 phosphorylation drives progressive cardiac dysfunction and early mitochondrial alterations, which can be mitigated by an elamipretide-derived peptide to improve survival.
Mitochondrial-targeted peptides may attenuate troponin-driven dysfunction in models; leaves open human translation.
Protein kinase C (PKC) targeted thin filament cardiac troponin I (cTnI) Ser43/45 phosphorylation (p-S43/45) increases during heart failure (HF). Chronic cTnI p-S43/45 causes contractile dysfunction in cardiac myocytes, but the in vivo impact is less clear. To investigate the in vivo impact of this cluster, three lines of transgenic mice were generated with high (HE-), moderate (ME-), and low (LE-) phospho-mimetic cTnIS43/45D (SD) replacement of endogenous cTnI within sarcomere thin filament. Each mouse line developed chronic in vivo and/or cellular contractile dysfunction, which initiated structural remodeling and a progressive deterioration in cardiac function. Higher cTnISD replacement levels accelerated the rate of deterioration and progression to end-stage heart failure. In further work, cTnISD initiated sarcomere communication to produce early alterations in mitochondria prior to the progressive deterioration in cardiac performance. Specifically, early reductions developed in mitochondrial/nuclear DNA, mitochondrial master regulator gene expression, electron transport proteins, and anti-oxidants along with increased mitochondrial-related oxidative stress prior to extensive remodeling in cTnISD mice. In addition, cTnISD mice developed early differences in mitochondrial ultrastructure and evidence favoring fusion over fission compared to non-transgenic (ntg) littermates. A second generation peptide derived from elamipretide improved survival and slowed the progression of remodeling and contractile dysfunction. Overall, the results demonstrate chronic cTnISD causes cardiac dysfunction and initiates early mitochondrial responses that serve as an important driver of a progressive deterioration in cardiac performance to end-stage HF.
No takes yet. Share an insight, caveat, or question.
Ravichandran et al. (2026) studied this question. Chronic cTnIS43/45D phospho-mimetic replacement causes dose-dependent cardiac dysfunction with early mitochondrial impairment, accelerating progression to end-stage heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: